MACE配型在肿瘤临床血小板输注中的应用研究  

Research on platelet crossmatch by MACE in platelet transfusion of tumor patients

作　　者：郝宝岚[1] 王艳[1] 邵树军[1] 林常青[1] 董晓峰[1] 

机构地区：[1]河南省肿瘤医院输血科,郑州450008

出　　处：《中国卫生检验杂志》2012年第12期2852-2854,共3页Chinese Journal of Health Laboratory Technology

基　　金：河南省医学科技攻关项目(2011020167)

摘　　要：目的:为反复输注血小板的肿瘤患者提高输注疗效。方法:输注血小板5次以上肿瘤患者血样,用GTI试剂MACE与单采血小板进行交叉配型同时进行抗体检测,对配型不合者进行抗体分析。用CCI指标观察临床输注效果。结果:MACE交叉配型93次,相合者77例,占82.80%,不合者16例,占17.20%。16例配型不合者均表达HLAI类抗体,同时合并GPⅡb/Ⅲa抗体者4例。CCI显示配型结果与临床输注效果显著相关。结论:MACE配合型输注能有效解决因血小板抗体而致的输注无效。影响输注的免疫因素主要与HLA抗体的产生有关,对GPⅡb/Ⅲa糖蛋白复合物抗体的检测有一定的临床意义。Objective：To improve the clinical effect for tumor patients who have frequently received platelet transfusion.Methods： Platelet crossmatch and antibody detection were carried out by using GTI MACE kit with the plasma of those mentioned tumor patients and fresh apheresis platelets.Different types of antibodies in those dismatched cases were analyzed and clinical effect was monitored by the count of CCI.Results： There were 77 matched cases and 16 dismatched cases among the 93 times of platelet crossmatch.16 dismatched cases were confirmed to contain HLA-I antibody and 4 cases were confirmed to combine with HPA antibody to GPⅡb/Ⅲa.The result of platelet crossmatch positively correlated with clinical effect observed by CCI.Conclusion： Platelet crossmatch can effectively resolve the problem of platelet transfusion refractoriness caused by platelet antibodies.Antibodies to HLA is the main immunological factor and the detection of antibodies to GPⅡb/Ⅲa is significant in clinical practice.

关 键 词：MACE 肿瘤 血小板 HLA HPA 抗体 

分 类 号：R457.1[医药卫生—治疗学]